Startup profile · funding coverage
Prima Mente funding, valuation and investors
Biological foundation models for understanding complex disease.
Keep track of Prima Mente
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Not publicly disclosed
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
Stage not recorded · London, United Kingdom
Overview
London-based AI biology company building foundation models and investigating disease mechanisms. NVIDIA named it as an intended investment recipient in an October 13, 2026 announcement. No amount, valuation or completed financing was disclosed.
Why Prima Mente is interesting
The investment thesis depends on whether model outputs yield useful biological evidence and eventually commercial value. Computational findings should remain separate from clinical validation.
Product & use cases
Develops biological foundation models, including Pleiades, and applies them to areas such as neuroscience and neurodegenerative disease.
Key facts
- NVIDIA investment planned and amount undisclosed as of October 13, 2026 primary announcement.
Competitive landscape
Competes within AI-driven biology, where data quality, experimental confirmation and differentiated access to biological context are important. A strategic technology partner does not by itself validate a therapeutic result.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Prima Mente's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.